December 2, 2025Press releaseVisCardia Secures $40 Million Growth Financing to Advance VisONE™ Heart Failure Therapy Toward PMA ApprovalRead
June 10, 2025Press releaseVisCardia Wins Inaugural MedTech Innovator Impact Award at 32nd Annual Medical Device & Digital Health ConferenceRead
May 21, 2025Press releaseVisCardia Honored with Prestigious Innovation Award at EuroPCR 2025 for Groundbreaking Heart Failure TherapyRead
April 4, 2025Press releaseACC.25 Panel of Experts Awards VisCardia Top Honors for Innovation in MedTechRead
November 5, 2024Press releaseCMS Agrees With VisCardia on the Value of Synchronized Diaphragmatic StimulationRead
July 30, 2024Press releaseVisCardia Receives US FDA IDE Approval to Start the RECOVER HF Clinical StudyRead
June 17, 2021Press releaseVisCardia Selected in Top 50 Medical Device Start-Ups by MedTech Innovator to Participate in a Global Flagship Showcase and Accelerator ProgramRead
March 16, 2021Press releaseVisCardia Announces Issuance of American Medical Association CPT® Category III Codes for Synchronized Diaphragmatic Stimulation (SDS®)Read
April 23, 2020Press releaseVisCardia Announces Its Novel Heart Failure Therapy Receives Breakthrough Device Designation From the FDARead
April 22, 2019Press releaseVisCardia Announces Completion of Enrollment and Three Month Follow-Up Visits for Its VisONE® Heart Failure Pilot StudyRead
August 1, 2018Press releaseVisCardia Announces First Implant of the VisONE® System for Treating Heart FailureRead
February 1, 2017Press releaseVisCardia Completes $12.5 Million Series B Financing and Assets Transfer to Develop Proprietary Therapeutic Heart Failure Application and Appoints Michael Mirro M.D. as Director of Medical AffairsRead
